XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenues $ 57,763 $ 21,958 $ 92,392 $ 47,577
Operating expenses:        
Research and development 45,287 36,288 128,289 107,593
General and administrative 16,177 14,918 50,223 46,633
Total operating expenses 61,464 51,206 178,512 154,226
Loss from operations (3,701) (29,248) (86,120) (106,649)
Interest and other income, net 2,430 1,887 5,910 6,729
Loss before taxes (1,271) (27,361) (80,210) (99,920)
Income tax expense (237) 0 (237) 0
Net loss (1,508) (27,361) (80,447) (99,920)
Net income (loss) attributable to non-controlling interest 42 (54) (55) (179)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (1,550) $ (27,307) $ (80,392) $ (99,741)
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share) $ (0.01) $ (0.24) $ (0.61) $ (0.90)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 141,100 115,710 132,079 110,837